Established in 1999, the Bench to Bedside (B2B) Program funds research teams seeking to translate basic scientific findings into therapeutic interventions for patients and to increase understanding of important disease processes.
The Bench to Bedside (B2B) Program accomplishes this mission by addressing barriers, such as the traditional silos between basic and clinical researchers in biomedical research, which can hinder progress toward finding new therapeutics for patients in need; B2B teams involve basic and clinical researchers, often from different NIH Institutes and Centers. In 2006, the B2B program's charge was expanded to unite the efforts of intramural and extramural NIH researchers. Intramural science refers to research that takes place on an NIH campus under the auspices of federal employees, while extramural research is funded by NIH and conducted by investigators and institutions outside of NIH.
The B2B program exemplifies the benefits associated with intramural – extramural collaborations; the extramural community gains access to the Clinical Center's unique resources, and the intramural community can pursue innovative research with extramural investigators.
A B2B award provides up to $135,000 a year for two years. Projects, which are funded by various NIH offices and institutes* , have represented several research categories: AIDS, rare diseases, behavioral and social sciences, minority health and health disparities, women's health, rare diseases drug development, pharmacogenomics, and general.
Through the end of the 2011 program cycle, about 700 principal and associate investigators have collaborated on 192 funded projects with approximately $44M distributed in total bench-to-bedside funding. The introduction of extramural collaborations in 2006 has resulted in partnerships at 68 institutions, over 20 of which are Clinical and Translational Science Award sites.
Text version of the slideshow
NOTE: PDF documents require the free Adobe Reader.
Adobe Flash requires the free Adobe Flash Player to run.
